Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanping Luo

Showing results (171-180 of 176) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 176 results.
Zhonghua Yi Xue Za Zhi|December 26, 2015
[Analysis of pathogen spectrum and resistance of clinical common organisms causing bloodstream infections, hospital-acquired pneumonia and intra-abdominal infections from thirteen teaching hospitals in 2013]Chunjiang Zhao, Hongbin Chen, Hui Wang, et al.
BMC Infectious Diseases|March 8, 2017
Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014Qiwen Yang, Hui Zhang, Yao Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.
Magnetic Resonance Imaging|March 16, 2019
Repeatability and reproducibility of longitudinal relaxation rate in 12 small-animal MRI systemsJohn C Waterton, Catherine D G Hines, Paul D Hockings, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCherrie K Donawho, Yan Luo, Yanping Luo, et al.
Pageof 18

Showing results (171-180 of 176) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 176 results.
Zhonghua Yi Xue Za Zhi|December 26, 2015
[Analysis of pathogen spectrum and resistance of clinical common organisms causing bloodstream infections, hospital-acquired pneumonia and intra-abdominal infections from thirteen teaching hospitals in 2013]Chunjiang Zhao, Hongbin Chen, Hui Wang, et al.
BMC Infectious Diseases|March 8, 2017
Antimicrobial susceptibilities of aerobic and facultative gram-negative bacilli isolated from Chinese patients with urinary tract infections between 2010 and 2014Qiwen Yang, Hui Zhang, Yao Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.
Magnetic Resonance Imaging|March 16, 2019
Repeatability and reproducibility of longitudinal relaxation rate in 12 small-animal MRI systemsJohn C Waterton, Catherine D G Hines, Paul D Hockings, et al.
Molecular Cancer Therapeutics|May 2, 2006
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorDaniel H Albert, Paul Tapang, Terrance J Magoc, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCherrie K Donawho, Yan Luo, Yanping Luo, et al.
Pageof 18